Phase 4 N=24 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Gout
Primary: BMI — 33.4 kg/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=142 Uric Acid and Hypertension in African Americans
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline — 3.44; -0.83 mm Hg — p=0.059
Phase 2 N=36 A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
Asymptomatic Hyperuricemia
Primary: Change From Baseline in Peak Urinary Excretion of Uric Acid (UA) on Day 7 — -12.87; -13.15 milligrams (mg)
Phase 2 N=26 Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants
Phase 4 N=47 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure
Prehypertension · Gout · Pulse Wave Velocity
Primary: Changes in 24 Hour Blood Pressure
Phase 2 N=253 Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Heart Failure · Elevated Serum Uric Acid
Primary: A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged. — 58; 58; 54; 43 participants
Phase 2 N=204 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Gout and Hyperuricemia
Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001
Phase 2 N=60 Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.
Hyperuricemia
Primary: Serum Uric Acid<6 mg/dL at Week 4 — 0; 1; 1 Participants
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Phase 4 N=1,732 Allopurinol Outcome Study
Gout
Primary: Safety of Allopurinol — 55.1 percentage of subjects
N/A N=31 Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
Obesity · Metabolic Syndrome · Hyperuricemia
Primary: Percent Increase in Insulin-stimulated Glucose Uptake — 231; 162; NA; 156 % incr. in insulin-mediated gluc. uptake
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 4 N=45 Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
Type 1 Diabetes · Diabetic Nephropathy · Diabetic Kidney Disease
Primary: Change in Urine Uric Acid Concentration (Increased Solubility) by Assay — 23.81; 22.30 mg/dl
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
N/A N=40 A Controlled Study of Uric Acid on the Progression of IgA Nephropathy
IgA Nephropathy
Primary: Change in Renal Function as Measured With eGFR — 68.9; 73.2 eGFR(min/ml)
Phase 4 N=196 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
Gout
Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298
Phase 1 N=18 A Food-Drug Interaction Study of Serum Urate After Oral Inosine
Healthy
Primary: Cmax: Maximum Observed Serum Urate Concentration — 6.6; 6.4 mg/dL
Phase 4 N=9 Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion
Adenine Phosphoribosyltransferase Deficiency
Primary: Urinary 2,8-dihydroxyadenine Excretion — 116; 45; 13 mg/24-h — p=<.05
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
N/A N=1,705 Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
Hypertension
Primary: Serum Uric Acid (SUA) Level — 6.4; 6.6 mg/dL — p=<0.01
Phase 3 N=214 Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Gout
Primary: Number of Subjects With an sUA Level That is < 6.0 mg/dL — 32; 2 Number of Subjects — p=<0.0001
Phase 3 N=143 Open-Label Lesinurad Monotherapy Extension Study in Gout
Gout
Primary: Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL — 68 Subjects
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
N/A N=43 The Diet Gout Trial
Gout · Hyperuricemia
Primary: Uric Acid Level — 8.23; 8.03 mg/dL
Phase 2 N=861 A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
Primary: Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM) — 0.8300; 1.043; 0.8369; 0.8499 mg/g…
Phase 3 N=298 Study of Urate Elevation in Parkinson's Disease, Phase 3
Parkinson's Disease
Primary: Rate of Clinical Decline — 11.116; 9.860 score per year — p=0.183